DUKE UNIVERSITY
SCHOOL OF MEDICINE
DUKEHEALTH.ORG
| Active Clinical Trials |
| | CTCL Trials | Hair Trials | Blistering Disorders | Psoriasis Trials |
Duke Dermatology
Active Clinical Trials: Psoriasis
2008-2009
Protocol Title: An Open-Label Study to Determine the Safety and Efficacy of Alefacept in Subjects
with Chronic Plaque Psoriasis Who have Failed Anti-TNF Therapy", Protocol #ER-07-001.
Principal Investigator: Dr. John Murray
Clinical Trial Coordinator:
Purpose: The purpose of this study is to determine the efficacy of alefacept when administered
as an intramuscular injection to patients with chronic plaque psoriasis who have
been treated with anti-TNF therapy, but have not responded with a 75% reduction
of Psoriasis Area and Severity Index (PASI) Score or a Physician Global Assessment
(PGA) score of 'almost clear' or 'clear'
Primary Objective is to determine the safety and efficacy of Amevive 15 mg IM weekly in subjects
with chronic plqque psoriasis who have not sufficiently responded to an anti-TNF
agent.
Secondary objective is to determine the duration of response to point of relapse and to determine
length of response time before retreatment with alefacept is necessary.
Protocol Title: Raptiva Epidemiologic Study of Psoriasis Outcomes and Safety Events (RESPONSE)
in Patients With Chronic Moderate to Severe Plaque Psoriasis.
Principal Investigator: Dr. John Murray
Clinical Trial Coordinator:
Purpose: This study will assess the long-term safety profile of Raptiva in patients
with chronic moderate to severe plaque psoriasis who are candidates for treatment
with Raptiva.
Protocol Title: A Multicenter, Open-label Study to Assess the Efficacy and Safety of Infliximab
(REMICADE®) Therapy in Patients With Plaque Psoriasis Who Had an Inadequate Response
to Etanercept (ENBREL®)
Principal Investigator: Dr. John Murray
Clinical Trial Coordinator:
Purpose: The primary objective of this study is to assess the efficacy at Week 10 of
treatment with infliximab in patients with plaque psoriasis who have had an inadequate
response to therapy with etanercept despite at least 4 months of treatment.
The major secondary objective of this study is to evaluate the benefits of switching
psoriasis therapies from etanercept to infliximab on the outcomes of time to onset
of clinical response and health related quality of life. Safety will be assessed
throughout the study.
Protocol Title: Observational Post-marketing Safety Surveillance Registry of Enbrel (etanercept)
for Treatment of Psoriasis: OBSERVE-5TM Protocol Number 20040210
Principal Investigator: Dr. John Murray
Clinical Trial Coordinator:
Purpose: The purpose of this study is to prospectively gather and evaluate information
on the long-term safety of Enbrel in a large number of subjects with plaque psoriasis.
DHTS STRATEGIC WEB SERVICES